 Phase I/II study cyclophosphamide doxorubicin fluorouracil leucovorin treatment metastatic adenocarcinoma Leucovorin cytotoxicity fluorouracil patients colorectal cancer efficacy combination chemotherapy maximum dose leucovorin use combination cyclophosphamide doxorubicin phase I/II trial patients doses leucovorin days cyclophosphamide day doxorubicin day constant dose cohorts patients days Cycles weeks Significant mucositis diarrhea myelosuppression patients days contrast dose days patients granulocyte count nadirs first cycle therapy platelet counts addition patients dose significant mucosal toxic effects insufficient recovery second course day patients assessable breast cancer complete partial responses response rate Leucovorin modulation combination chemotherapy cyclophosphamide doxorubicin active regimen treatment metastatic breast cancer Further study addition leucovorin activity regimen